Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cigna GroupCI · Entity 550 | CEO Evernorth | May 12, 2021 | May 13, 2021 |
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | Director | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cigna Group
Report date May 12, 2021 · Filed May 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | IndirectBy Trust | 29,783 |
Reported balance
After 2021-05-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-05-12 · Gift · Disposed 11,150 · Balance 29,783 |
| Common Stock, $.01 Par ValueSEC Table I · non-derivative | Direct | 31,484 |
Reported balance
Holding disclosure · report date 2021-05-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 31,484 |
QUEST DIAGNOSTICS INC
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 477 |
Reported balance
After 2026-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-01 · Grant · Acquired 135 · Balance 477 F1: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Express Scripts Holding Co.
Report date December 20, 2018 · Filed December 21, 2018
Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-12-20 transaction · row 5
3 source rows · reconciled sequenceRow 1 · 2018-04-06 · Gift · Disposed 45,327 · Balance 139,736.667 Row 3 · 2018-07-10 · Gift · Disposed 4,482 · Balance 135,254.667 Row 5 · 2018-12-20 · Disposition to issuer · Disposed 135,254.667 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 152,779 |
Reported balance
After 2018-04-06 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-04-06 · Gift · Acquired 45,327 · Balance 152,779 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 157,261 |
Reported balance
After 2018-07-10 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-07-10 · Gift · Acquired 4,482 · Balance 157,261 |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2018-12-20 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-12-20 · Disposition to issuer · Disposed 157,261 · Balance 0 F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.17 · Expires 2020-03-06 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-12-20 · Disposition to issuer · Disposed 33,069 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.15 · Expires 2021-03-05 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-12-20 · Disposition to issuer · Disposed 94,140 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.61 · Expires 2022-02-24 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-12-20 · Disposition to issuer · Disposed 43,081 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.83 · Expires 2025-03-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-12-20 · Disposition to issuer · Disposed 106,240 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.57 · Expires 2026-03-09 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-12-20 · Disposition to issuer · Disposed 140,115 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $72.74 · Expires 2026-05-04 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-12-20 · Disposition to issuer · Disposed 123,064 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.62 · Expires 2027-03-08 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-12-20 · Disposition to issuer · Disposed 271,714 · Balance 0 F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted. |
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2018-12-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-12-20 · Disposition to issuer · Disposed 2,388.0983 · Balance 0 F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan. F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock. F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement. F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the agreement and plan of merger ("Merger Agreement") between the Issuer and Cigna Corporation, Halfmoon Parent, Inc., Halfmoon I, Inc. and Halfmoon II, Inc., upon closing of the merger of Halfmoon II, Inc. with and into the Issuer (the "Merger"), each common share of the Issuer was converted into the right to receive 0.2434 shares of Halfmoon Parent, Inc. common stock and $48.75 in cash. Each restricted stock unit was converted into a unit with respect to common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F2: The options vest on varying dates pursuant to the terms of the plans and/or agreements under which they were granted.
F3: Pursuant to the Merger Agreement, upon closing of the Merger, the option was converted into an option to purchase common shares of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F4: Phantom Stock Unit credited under the Company's Executive Deferred Compensation Plan.
F5: Upon distribution, each phantom stock unit would have converted into one share of the Issuer's common stock.
F6: Pursuant to the Merger Agreement, upon closing of the Merger, each phantom stock unit was converted into a stock unit relating to the common stock of Halfmoon Parent, Inc. in accordance with the exchange ratio set forth in the Merger Agreement.
F7: Basic Company Credit by the Issuer to Reporting Person's Account in the Executive Deferred Compensation Plan; shares vest 3 (three) years after the plan year to which such credit relates.
Walgreens Boots Alliance, Inc.
Report date August 28, 2025 · Filed August 28, 2025
Section 16 reporting ended · disclosed 2025-08-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-08-28 transaction · row 1
1 source rowRow 1 · 2025-08-28 · Disposition to issuer · Disposed 1,332,014 · Balance 0 F1: Includes shares underlying restricted stock units ("RSUs"), inclusive of RSUs issued in lieu of dividends. F2: Pursuant to the Agreement and Plan of Merger, dated as of March 6, 2025 (the "Merger Agreement"), by and among Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), Blazing Star Parent, LLC, a Delaware limited liability company ("Parent"), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and the other affiliates of Parent named therein, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F3: At the effective time of the Merger (the "Effective Time") each share of Common Stock was automatically converted into the right to receive from Parent (i) $11.45 in cash, without interest thereon and subject to all applicable withholding (the "Per Share Cash Consideration"), and (ii) one divested asset proceed right issued by Parent or one of its affiliates subject to and in accordance with the divested asset proceed rights agreement (each, a "Divested Asset Proceed Right" and, collectively with the Per Share Cash Consideration, the "Per Share Consideration"). F4: Pursuant to the Merger Agreement, each RSU owned by the reporting person at the Effective Time was cancelled in exchange for the Per Share Consideration, provided that, payment of such consideration with respect to any RSUs that were unvested as of the Effective Time will remain subject to the Reporting Person's continued service as an employee, consistent with the vesting conditions applicable to such RSU immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares underlying restricted stock units ("RSUs"), inclusive of RSUs issued in lieu of dividends.
F2: Pursuant to the Agreement and Plan of Merger, dated as of March 6, 2025 (the "Merger Agreement"), by and among Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), Blazing Star Parent, LLC, a Delaware limited liability company ("Parent"), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and the other affiliates of Parent named therein, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent.
F3: At the effective time of the Merger (the "Effective Time") each share of Common Stock was automatically converted into the right to receive from Parent (i) $11.45 in cash, without interest thereon and subject to all applicable withholding (the "Per Share Cash Consideration"), and (ii) one divested asset proceed right issued by Parent or one of its affiliates subject to and in accordance with the divested asset proceed rights agreement (each, a "Divested Asset Proceed Right" and, collectively with the Per Share Cash Consideration, the "Per Share Consideration").
F4: Pursuant to the Merger Agreement, each RSU owned by the reporting person at the Effective Time was cancelled in exchange for the Per Share Consideration, provided that, payment of such consideration with respect to any RSUs that were unvested as of the Effective Time will remain subject to the Reporting Person's continued service as an employee, consistent with the vesting conditions applicable to such RSU immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantPhantom Stock Units · Derivative | 135 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-26-000090 · wk-form4_1790973218.xml · derivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477 Underlying: Common Stock · 135 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 20:34 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantPhantom Stock Units · Derivative | 144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-26-000060 · wk-form4_1783024458.xml · derivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342 Underlying: Common Stock · 144 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. Read SEC document |
| May 20, 2026 Filed May 21, 2026 20:56 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 1,142 | $0.00 | $0.00 |
DisclosureSEC source: 0001252016-26-000007 · wk-form4_1779396987.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,358 F1 · security: Represents an award of restricted stock units. F2 · balance_after: The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4 pursuant to the Amended and Restated Deferred Compensation Plan for Directors. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 21:16 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantPhantom Stock Units · Derivative | 198 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001022079-26-000035 · wk-form4_1775164614.xml · derivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198 Underlying: Common Stock · 198 shares Expires not disclosed F1 · derivative.exercise_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. F1 · derivative.expiration_date: Phantom stock units resulting from elective deferrals of a director's cash compensation pursuant to the Quest Diagnostics Incorporated Amended and Restated Deferred Compensation Plan for Directors and become payable in cash upon the reporting person's termination of service as a director. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 22:05 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 215 | $0.00 | $0.00 |
DisclosureSEC source: 0001252016-26-000004 · wk-form4_1773266699.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 215 F1 · security: Represents an award of restricted stock units. Read SEC document |
| August 28, 2025 Filed Aug 28, 2025 15:22 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | Disposition to issuerCommon Stock | 1,332,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-111920 · ownership.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes shares underlying restricted stock units ("RSUs"), inclusive of RSUs issued in lieu of dividends. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of March 6, 2025 (the "Merger Agreement"), by and among Walgreens Boots Alliance, Inc., a Delaware corporation (the "Company"), Blazing Star Parent, LLC, a Delaware limited liability company ("Parent"), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), and the other affiliates of Parent named therein, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent. F3 · price: At the effective time of the Merger (the "Effective Time") each share of Common Stock was automatically converted into the right to receive from Parent (i) $11.45 in cash, without interest thereon and subject to all applicable withholding (the "Per Share Cash Consideration"), and (ii) one divested asset proceed right issued by Parent or one of its affiliates subject to and in accordance with the divested asset proceed rights agreement (each, a "Divested Asset Proceed Right" and, collectively with the Per Share Cash Consideration, the "Per Share Consideration"). F4 · price: Pursuant to the Merger Agreement, each RSU owned by the reporting person at the Effective Time was cancelled in exchange for the Per Share Consideration, provided that, payment of such consideration with respect to any RSUs that were unvested as of the Effective Time will remain subject to the Reporting Person's continued service as an employee, consistent with the vesting conditions applicable to such RSU immediately prior to the Effective Time. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:19 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | Tax withholdingCommon Stock | 78,142 | $9.46 | $739,223.32 |
DisclosureSEC source: 0001618921-24-000144 · wk-form4_1730859547.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,298,376 F3 · kind: Disposition relating to the satisfaction of tax withholding obligations upon the settlement of award granted in accordance with Rule 16b-3. F2 · balance_after: Includes shares underlying restricted stock units issued in lieu of dividends (through October 31, 2024) on outstanding restricted stock units. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:19 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 762,032 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-24-000144 · wk-form4_1730859547.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,376,518 F1 · kind: Restricted stock unit award granted under the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (together with the related award agreement and the applicable election forms thereunder, the "Plan") vests in one-third increments on each of the first, second and third anniversaries of the November 1, 2024 date of grant, subject to acceleration or forfeiture in certain circumstances in accordance with the terms and conditions of the Plan. F2 · balance_after: Includes shares underlying restricted stock units issued in lieu of dividends (through October 31, 2024) on outstanding restricted stock units. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 07:29 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | PurchaseCommon Stock | 10,000 | $24.22 | $242,220.00 |
DisclosureSEC source: 0001618921-24-000006 · wk-form4_1704716986.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,122 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $24.15 to $24.25, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or any securityholder of the issuer, upon request, information regarding the number of shares sold at each price within the range indicated. F2 · balance_after: Includes shares underlying restricted stock units issued in lieu of dividends (through January 1, 2024) on outstanding restricted stock units. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 19:56 UTC | Walgreens Boots Alliance, Inc. WBA · Entity 16467 | GrantCommon Stock | 562,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001618921-23-000101 · wk-form4_1699055797.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 562,324 F1 · kind: Restricted stock unit award granted under the Walgreens Boots Alliance, Inc. 2021 Omnibus Incentive Plan (together with the related award agreement and the applicable election forms thereunder, the "Plan") vests in one-third increments on each of the first, second and third anniversaries of the November 1, 2023 date of grant, subject to acceleration or forfeiture in certain circumstances in accordance with the terms and conditions of the Plan. Read SEC document |
| May 12, 2021 Filed May 13, 2021 21:37 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 11,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-008125 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 29,783 Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 6,087 | $0.00 Strike: $99.15 | $0.00 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · derivative · entry 7 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 6,087 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. F2 · derivative.exercise_date: This option was granted on February 24, 2012. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 6,087 | $99.15 | $603,502.92 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,484 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,600 | $0.00 Strike: $99.15 | $0.00 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · derivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,087 Underlying: Common Stock, $.01 Par Value · 14,600 shares Expires 2022-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. F2 · derivative.exercise_date: This option was granted on February 24, 2012. The option vested in three equal annual installments on the first, second and third anniversaries of the grant date. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 14,600 | $249.54 | $3,643,284.00 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,397 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. Read SEC document |
| April 15, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 14,600 | $99.15 | $1,447,534.52 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,997 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 12, 2021. Read SEC document |
| March 05, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 22,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,933 Read SEC document |
| March 05, 2021 Filed Apr 20, 2021 01:19 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 22,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-006856 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,397 Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,932 | $215.26 | $631,130.30 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 9 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 18,207 F5 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F10 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $214.73 to $215.72 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,800 | $214.07 | $385,334.82 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 8 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 21,139 F5 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F9 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $213.64 to $214.59 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 400 | $213.31 | $85,325.00 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 7 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 22,939 F5 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F8 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $212.64 to $213.58 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 400 | $215.77 | $86,306.00 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 23,339 F5 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F7 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $215.74 to $215.82 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 200 | $211.94 | $42,388.00 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 23,739 F5 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F6 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $211.58 to $212.30 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 8,016 | $210.31 | $1,685,844.96 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,123 F4 · shares: Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 6,270 | $209.90 | $1,316,073.00 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,139 F3 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 2,727 | $210.31 | $573,515.37 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,409 F2 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 01:27 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 15,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-004359 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,136 F1 · shares: The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2018-2020 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:20 UTC | Cigna Group CI · Entity 550 | GrantEmployee Stock Option (Right to Buy) · Derivative | 33,457 | $0.00 Strike: $213.80 | $0.00 |
DisclosureSEC source: 0001225208-21-003968 · doc4.xml · derivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,457 Underlying: Common Stock, $.01 Par Value · 33,457 shares Expires 2031-02-24 F2 · derivative.exercise_date: This option vests in three equal annual installments beginning March 1, 2022. Read SEC document |
| February 24, 2021 Filed Feb 27, 2021 01:20 UTC | Cigna Group CI · Entity 550 | GrantCommon Stock, $.01 Par Value | 7,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-003968 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,466 F1 · shares: These restricted shares vest in three equal annual installments beginning March 1, 2022. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:23 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,095 | $204.94 | $429,349.30 |
DisclosureSEC source: 0001225208-21-001889 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 23,939 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F5 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $204.41 to $205.39 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:23 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,849 | $205.75 | $380,426.02 |
DisclosureSEC source: 0001225208-21-001889 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 26,034 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $205.42 to $206.29 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 08, 2021 Filed Feb 8, 2021 23:23 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,200 | $203.88 | $244,653.12 |
DisclosureSEC source: 0001225208-21-001889 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 27,883 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $203.23 to $204.12 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:23 UTC | Cigna Group CI · Entity 550 | Tax withholdingCommon Stock, $.01 Par Value | 4,554 | $210.53 | $958,753.62 |
DisclosureSEC source: 0001225208-21-001889 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,450 F1 · shares: Represents shares withheld to satisfy tax obligations upon vesting of restricted shares. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 22:40 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 2,649 | $202.78 | $537,152.56 |
DisclosureSEC source: 0001225208-20-015133 · doc4.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 29,083 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $202.38 to $203.26 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 22:40 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 800 | $201.59 | $161,274.00 |
DisclosureSEC source: 0001225208-20-015133 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 31,732 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $201.05 to $202.03 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 28, 2020 Filed Dec 30, 2020 22:40 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 400 | $203.73 | $81,492.20 |
DisclosureSEC source: 0001225208-20-015133 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 32,532 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 24, 2020. F2 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $203.38 to $203.99 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 01, 2020 Filed Dec 30, 2020 22:40 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 3,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-015133 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 32,932 Read SEC document |
| December 01, 2020 Filed Dec 30, 2020 22:40 UTC | Cigna Group CI · Entity 550 | GiftCommon Stock, $.01 Par Value | 3,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-015133 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,004 Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 23:44 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,849 | $0.00 Strike: $160.66 | $0.00 |
DisclosureSEC source: 0001225208-20-013211 · doc4.xml · derivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 3,849 shares Expires 2021-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · derivative.exercise_date: This option was granted on March 5, 2014. The option vested in three equal annual installments on February 28, 2015, February 28, 2016, and February 28, 2017. Read SEC document |
| November 05, 2020 Filed Nov 6, 2020 23:44 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 3,849 | $160.66 | $618,389.19 |
DisclosureSEC source: 0001225208-20-013211 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 23:44 UTC | Cigna Group CI · Entity 550 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 41,357 | $0.00 Strike: $160.66 | $0.00 |
DisclosureSEC source: 0001225208-20-013211 · doc4.xml · derivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 Underlying: Common Stock, $.01 Par Value · 41,357 shares Expires 2021-03-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. F2 · derivative.exercise_date: This option was granted on March 5, 2014. The option vested in three equal annual installments on February 28, 2015, February 28, 2016, and February 28, 2017. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 23:44 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 41,357 | $195.46 | $8,083,639.22 |
DisclosureSEC source: 0001225208-20-013211 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,004 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 23:44 UTC | Cigna Group CI · Entity 550 | Exercise / conversionCommon Stock, $.01 Par Value | 41,357 | $160.66 | $6,644,510.74 |
DisclosureSEC source: 0001225208-20-013211 · doc4.xml · nonDerivative · entry 1 WENTWORTH TIMOTHY C · CIK 0001252016 · CEO Evernorth 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2020. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 600 | $212.54 | $127,525.50 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 8 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 29,083 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F9 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $211.985 to $212.91 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 500 | $213.41 | $106,707.00 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 7 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 29,683 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F8 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $212.99 to $213.93 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 400 | $214.51 | $85,805.24 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 6 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 30,183 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F7 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $214.07 to $214.95 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 200 | $215.14 | $43,028.00 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 5 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 30,583 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F6 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $215.11 to $215.17 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 5,311 | $210.61 | $1,118,536.43 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 4 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 30,783 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F5 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $210.02 to $211.01 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 4,000 | $211.32 | $845,267.60 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 3 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 36,094 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F4 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $211.04 to $211.88 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 22:18 UTC | Cigna Group CI · Entity 550 | SaleCommon Stock, $.01 Par Value | 1,500 | $212.55 | $318,831.00 |
DisclosureSEC source: 0001225208-20-008773 · doc4.xml · nonDerivative · entry 2 WENTWORTH TIMOTHY C · CIK 0001252016 · President, Health Services 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 40,094 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2020. F3 · price: Represents the weighted average price of the shares sold. The prices actually received ranged from $212.09 to $213.08 per share. The reporting person will provide to the issuer, any security holder of the issuer, or the Securities and Exchange Commission, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.